5.20
-6.64%
Close of 9 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Briacell Therapeutics
Its shares trade on Toronto Stock Exchange under the ticker BCT.TO. It has been listed since 12 October 2006.
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company, which engages in the development of immunotherapies for treatment of cancer. The company is headquartered in West Vancouver, British Columbia. The company went IPO on 2006-10-12. The Company’s lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patient’s own cancer fighting cells to attack and destroy breast cancer tumors. The firm is advancing its targeted immunotherapy program by prioritizing a Phase II clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor. The firm is focused on conducting a Phase I/IIa clinical trial of Bria-IMT in a combination study with Incyte’s immune PD-1 inhibitor, retifanlimab, in advanced breast cancer. The firm is also developing Bria-OTS, an off-the-shelf personalized approach to whole cell cancer immunotherapy. The Bria-OTS immunotherapy is based on a patient’s HLA-type. Its pipeline also includes Bria-Pros, Bria-Lung, Bria-Mel and sCD80, which are in development to treat various cancers.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 12 Oct 2006
- Website
- briacell.com ↗
Leadership
Pay as last reported
- Mr. Jamieson BondarenkoNon-Executive Independent Chairman of the Board, since 2019$664,107
- Dr. William WilliamsPresident, Chief Executive Officer, Director, since 2016$1.1m
- Mr. Gadi LevinChief Financial Officer, Corporate Secretary$520,730
- Dr. Miguel Lopez-LagoChief Scientific Officer, since 2022$393,608
- Dr. Giuseppe Del PrioreChief Medical Officer$780,845
- Mr. Vaughn Embro-pantalonyIndependent Director$175,880
- Dr. Jane GrossIndependent Director$146,860
- Mr. Martin SchmiegIndependent Director$166,864
- Dr. Rebecca TaubIndependent Director$141,868
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Bria-IMT is a cell-based patented immunotherapy for breast cancer treatment.
- Bria-OTS offers an off-the-shelf personalized immunotherapy based on HLA-type.
- Bria-IMT is being tested in a Phase I/IIa clinical trial with retifanlimab.
Weaknesses
- The company has no approved drugs for cancer treatment as of 2023.
- Bria-IMT is still in Phase II clinical trials for breast cancer.
- The company focuses on multiple cancer types without approved therapies.
Opportunities
- Bria-IMT could expand to other cancer types beyond breast cancer.
- The combination with Incyte’s retifanlimab may improve treatment outcomes.
- Bria-OTS could enter the personalized immunotherapy market.
Threats
- Bria-IMT faces competition from other immunotherapies in development.
- The Phase II trial results may not meet efficacy standards.
- Regulatory approval delays could impact Bria-IMT development.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.